Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Phosphoinositide 3-kinase (PI3K) signaling
- Class Ia PI3K's mediate growth factor signaling
- Receptor tyrosine kinase signaling pathway
- Logic network
- Loss-of-function mutations in tumor suppressors
- Sporadic mutations
- Drug targets
- Regulation of metabolism by PI3K AKT signaling
- NVP BEZ235
- Targets of BEZ235 (1)
- Targets of BEZ235 (2)
- Generation of mice with mutant PI3K p110a
- Lung adenocarcinoma requires mutant PI3K
- HIF-1alpha
- Visualizing lung tumors using FDG PET
- mTOR inhibition does not reduce tumor volume
- Will a PI3K inhibitor kill K-Ras driven tumors?
- AKT inhibition does not affect tumor size or activity
- Effects of BEZ235 in K-Ras mutant tumors
- BEZ235 specifically kills PI3K driven tumors
- ARRY 886
- PI3K with MEK inhibitors eradicates K-Ras tumors
- Blocking the PI3K and MAP Kinase pathways
- Inhibition of S6 kinase in K-Ras tumors
- Summary
- References
Topics Covered
- Phosphoinositide 3-kinase (PI3K) signaling
- Class Ia PI3K's and the mediation of growth factor signaling
- The receptor tyrosine kinase signaling pathway
- Loss-of-function mutations in tumor suppressors
- Sporadic mutations
- Drug targets
- Regulation of metabolism by PI3K AKT signaling
- Targets of the drug NVP BEZ235
- Generation of mice with mutant PI3K p110a
- How lung adenocarcinoma requires mutant PI3K
- HIF-1alpha
- Visualizing lung tumors using FDG PET
- How mTOR inhibition does not reduce tumor volume
- Will a PI3K inhibitor kill K-Ras driven tumors?
- How AKT inhibition does not affect tumor size or activity
- Effects of BEZ235 in K-Ras mutant tumors
- How BEZ235 specifically kills PI3K driven tumors
- The drug ARRY 886
- How PI3K with MEK inhibitors eradicates K-Ras tumors
- Blocking the PI3K and MAP Kinase pathways
- Inhibition of S6 kinase in K-Ras tumors
Talk Citation
Cantley, L. (2010, November 30). Role of the PI 3-kinase signaling pathway in cell regulation and human disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/ZQRQ1624.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Lew Cantley, Consultant: Novartis.
Hide